ArticleLife (Basel, Switzerland)2026
Assistive Technologies to Guide the Management of Volume Overload in Hemodialysis Patients: Are They Ready for Implementation in Daily Clinical Practice?
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypervolemia in hemodialysis patients is often covert and physical examination is frequently inaccurate in diagnosing the presence of subclinical volume expansion. Newer technologies, such as relative blood volume monitoring during dialysis, bioimpedance spectroscopy and lung ultrasound, offer promise for a more accurate assessment of volume status in these patients. Prospective observational studies support the notion that hypervolemia, as assessed with these assistive methods, is a strong and independent predictor of adverse cardiovascular outcomes and mortality in hemodialysis patients. However, randomized controlled trials and meta-analyses have failed to demonstrate that as compared with usual care, a volume management strategy based on the use of these assistive techniques is more effective in mitigating the risk of adverse intradialytic events and in improving long-term cardiovascular outcomes. In this article, we explore the question: whether assistive technologies are ready for implementation in daily clinical practice for the long-term management of volume overload in hemodialysis patients. We critically evaluate evidence from recently completed randomized trials and provide directions for future research in this important scientific area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.